'We Have The Potential To Address At Least $1 Bn Of The SSI Market'
Express Pharma|September 1-15, 2017

Recently, CHD Bioscience signed a global licensing agreement with Dr Reddy's Laboratories for developing and commercialising its phase III candidate DFA-02. Michael Handley, CEO, CHD Bioscience, talks about the plans for clinical trials of the molecule, with Usha Sharma.

Usha Sharma
'We Have The Potential To Address At Least $1 Bn Of The SSI Market'

What is the progress on DFA-02 clinical studies? Tell us more about its prospects.

DFA-02 is positioned to enter into a phase III clinical study for mitigation of complex abdominal infections in high risk patient populations. CHD Bioscience is currently in discussions with the FDA on the biostatistical powering and the study design. We will have a Type C meeting in the coming months to determine study design and study size. CHD believes DFA-02 has a place in the acute care setting beyond complex abdominal infections and we will be exploring other indications in cardiovascular surgeries and complex bone fixation surgeries.

When will DFA-02 enter phase III studies? When is it likely to commence?

Initiation of the phase III study is dependent on several factors, the most important being FDA approval of the study design and study size. We anticipate enrolling the first patient in the first half of 2018.

Denne historien er fra September 1-15, 2017-utgaven av Express Pharma.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra September 1-15, 2017-utgaven av Express Pharma.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA EXPRESS PHARMASe alt
Powerful Process Control with IND500x Weighing Indicators
Express Pharma

Powerful Process Control with IND500x Weighing Indicators

Ensuring consistent quality in hazardous environments, particularly in Ex-Areas (Zone 1/21, Division 1), is a critical aspect of industrial operations. The IND500x weighing indicators from METTLER TOLEDO provide a robust solution for these challenging settings, offering optimized safety and productivity.

time-read
1 min  |
November 2024
Ensuring clean room integrity with prime clean reset high-speed doors
Express Pharma

Ensuring clean room integrity with prime clean reset high-speed doors

Prime Clean Reset high-speed doors ensure airtight seals, minimising air permeability and contamination in clean rooms. Designed for sensitive environments, they enhance operational efficiency and meet rigorous regulatory standards, making them ideal for pharmaceutical and biotech industries

time-read
3 mins  |
November 2024
Complete environmental monitoring solution - testo Saveris Pharma
Express Pharma

Complete environmental monitoring solution - testo Saveris Pharma

There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.

time-read
3 mins  |
November 2024
Adaptive Manufacturing:-The new flexibility in medical device assembly
Express Pharma

Adaptive Manufacturing:-The new flexibility in medical device assembly

Unlike traditional, rigid production lines, B&R's adaptive machines seamlessly adjust to the requirements of each device, dynamically adapting to each unique process

time-read
3 mins  |
November 2024
Reshaping pharma safety with active packaging innovations
Express Pharma

Reshaping pharma safety with active packaging innovations

CILICANT is revolutionising active packaging with solutions tailored for the most sensitive formulations. Meet the innovators driving stability, safety, and impurity control in pharma packaging at CPhI India

time-read
1 min  |
November 2024
UNLOCKING GROWTH FRONTIERS
Express Pharma

UNLOCKING GROWTH FRONTIERS

Vadodara Pharma Summit 2024 brought together industry leaders and experts to highlight the city's pivotal role in India's pharma landscape and explore collaborative strategies to strengthen India's pharma innovation ecosystem

time-read
9 mins  |
November 2024
Optimising cloud provisioning for pharmaceutical compliance and operational excellence
Express Pharma

Optimising cloud provisioning for pharmaceutical compliance and operational excellence

Suresh Perikala, Senior Engineering Lead - DevOps and Cloud Engineering Practice, Altimetrik

time-read
3 mins  |
November 2024
Accelerating pharma's sustainability efforts
Express Pharma

Accelerating pharma's sustainability efforts

Avinaw Prasad, Director, Climate Change & Sustainability, Deloitte India explains why integrating sustainability into the core pharma business strategy is essential for long-term success, analyses key focus areas and policy pushes which can incentivise companies to further evolve on the sustainability path

time-read
5 mins  |
November 2024
Drug Repurposing: Unlocking access to rare solutions
Express Pharma

Drug Repurposing: Unlocking access to rare solutions

Drug repurposing, a quick, cost-effective path to deliver existing treatments to patients, can serve to expedite and expand healthcare access for patients with rare diseases

time-read
8 mins  |
November 2024
Optimising spend, maximising growth
Express Pharma

Optimising spend, maximising growth

Express Pharma, in partnership with IPA and CHEMEXCIL, powered by SAP, recently organised a thought leadership conclave on 'Reimagining spend management and supply chain' where cross functional experts explored strategies to drive value through supply chain transformation

time-read
7 mins  |
November 2024